Teva Launches AHZANTIVE, Expanding Biosimilars Footprint in Europe
Event summary
- Teva launched AHZANTIVE®, a biosimilar to Eylea® (aflibercept), in Europe on May 2026, targeting retinal diseases.
- The launch covers France, Germany, Spain, and The Netherlands, with additional markets expected later in 2026.
- AHZANTIVE received European Commission approval in 2025 for treating Neovascular Age-Related Macular Degeneration (nAMD) and other retinal conditions.
- Teva partners with Klinge Biopharma GmbH and Formycon AG for commercialization in major European markets and Israel.
- Teva’s biosimilars portfolio now includes 11 marketed products and 13 in the pipeline across oncology, immunology, ophthalmology, and respiratory care.
The big picture
Teva’s launch of AHZANTIVE aligns with its 'Pivot to Growth' strategy, reinforcing its commitment to biosimilars and expanding its presence in ophthalmology. The move reflects broader industry trends toward increasing access to affordable biologic medicines, particularly in high-need therapeutic areas like retinal diseases. Teva’s strategic partnerships and commercial capabilities will be key to sustaining this growth.
What we're watching
- Market Penetration
- How quickly Teva can expand AHZANTIVE’s reach beyond initial European markets and capture market share from Eylea.
- Regulatory Dynamics
- Whether AHZANTIVE’s approval and commercialization will face regulatory hurdles in new markets.
- Competitive Pressure
- The pace at which Regeneron and other competitors respond to Teva’s biosimilar entry in the ophthalmology space.
Related topics